Secukinumab is under clinical development by Novartis and currently in Phase II for Unspecified Dermatological Disorders.

conference that will make the case for Cosentyx (secukinumab) in a highly competitive market. Cosentyx is a key drug for Novartis, as it is part of the company’s plan to replace lost sales from ...

Please note NiYondashay is a COSENTYX ® (secukinumab) patient and has been compensated for her time. Continue reading for ...